Galenica AG (0ROG) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to this media analyst conference of the Galenica Group. We are very happy that this spring day you came here to Zurich to join us here on the live stream. Everybody is welcome. We will start with the financial results 2025 by our CFO and then we will have a moderated discussion, a brief one regarding the strategy and priorities. And there will always be sufficient time for your Q&A here in the room, but also from the live stream, of course. So I would now, without further ado, pass the floor to you, the CFO, Jan-Jan Vlesinger. Thank you. Thank you, Iris, and also a warm welcome from me to the guests here in Zurich and all to those taking part via the webcast. We can look back on a successful year 2025. Galenigra grew strongly by 5.5%, both in the logistics and IT segment with 4.8%, and especially in the segment products and care with a growth rate of 6.8%. In logistics and IT, we benefited from the strong market growth and grew in line with the market in terms of value in both the pharmacy and the physician's segments. The strong growth in the product and care segment is a combination of a strong organic growth and successful expansion. we were able to see organic growth in our market share in the pharmacy segment and also acquired additional attractive locations. One highlight was certainly in 2025, in September, the acquisition of Labor Team, which accounted for around 1% of the group's overall sales growth. The strong growth also laid the foundation for a positive development in profitability. EBIT rose by a strong 11.3% to 234.8 million francs in 2025. And this positive development was supported by... positive special factors totaling 6.2 million. These resulted from two competition proceedings in which the penalties were significant...